<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mild cognitive impairment: Epidemiology, pathology, and clinical assessment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mild cognitive impairment: Epidemiology, pathology, and clinical assessment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mild cognitive impairment: Epidemiology, pathology, and clinical assessment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald C Petersen, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 10, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H25688360"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mild cognitive impairment (MCI) is an intermediate clinical state between normal cognition and dementia. While specific subtle changes in cognition are frequently observed in normal aging, there is increasing evidence that some forms of cognitive impairment are recognizable as an early manifestation of a neurodegenerative condition that will ultimately lead to dementia [<a href="#rid1">1</a>]. MCI is a heterogeneous state, and there remains controversy over aspects of the construct. However, the utility of this paradigm centers around the recognition that dementia is not a dichotomous state; thus, refining our understanding of the layers of transition will improve the understanding of cognitive decline and ultimately benefit patients.</p><p>This topic will review the definition of MCI and related terms, as well as the epidemiology, pathology, and clinical assessment of MCI. The prognosis and treatment of MCI and topics related to dementia, including diagnosis, treatment, risk factors, and prevention of dementia, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5073.html" rel="external">"Treatment of Alzheimer disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5075.html" rel="external">"Prevention of dementia"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>MCI as a syndrome refers to cognitive impairment that does not meet the criteria for dementia but is more than normal aging. Several criteria for, and subtypes of, MCI have been proposed [<a href="#rid1">1-3</a>]. These criteria and subtypes differ somewhat, although there is considerable overlap. In general, these criteria include a measurable deficit in cognition in at least one domain, in the absence of dementia or impairment in everyday functioning.</p><p>As originally constructed, the concept of MCI emphasized memory impairment and its status as a precursor state for Alzheimer disease (AD). Subsequently, it was recognized that MCI can be heterogeneous in terms of clinical presentation, etiology, prognosis, and prevalence [<a href="#rid3">3-5</a>], and the construct was expanded to broaden the scope of MCI to other cognitive domains, thereby extending the syndromic early detection of other dementias in their prodromal stages [<a href="#rid6">6-8</a>]. These criteria were developed as a concept relating early changes in specific cognitive domains to those areas most commonly affected in the disorders (eg, memory problems and AD) [<a href="#rid8">8,9</a>].</p><p>Considerable judgment is required in making the distinction between impairments that are normal for the older adult population and, on the other extreme, that do not represent dementia. What constitutes impairment in functional status is different for each individual. Such distinctions draw upon clinical expertise and do not rely on psychometric testing alone. These appraisals can differ between assessors and this may account for some of the conflicting results in studies of this disorder, and while the diagnosis of dementia is similarly based on clinical judgment, most clinicians are more comfortable with making determinations of that severity. Some clinicians and investigators have challenged specific aspects of the criteria including the requirements for subjective cognitive complaints and intact daily function [<a href="#rid10">10-12</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Amnestic MCI</span><span class="headingEndMark"> — </span>Amnestic MCI (aMCI) is often thought of as a precursor to AD [<a href="#rid13">13</a>]. Across all MCI, aMCI is the most common subtype, with a ratio of 2:1 compared with nonamnestic MCI (naMCI), although relative prevalence of MCI subtypes has varied among studies [<a href="#rid14">14,15</a>].</p><p>Initially, MCI was used to refer to the amnestic subtype, but other subtypes have since been recognized. (See <a class="local">'Nonamnestic MCI'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single domain </strong>– aMCI refers to those individuals with significantly impaired memory who do not meet criteria for dementia. The criteria originally outlined for MCI are understood to identify specifically this type [<a href="#rid1">1,6</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Memory complaint, preferably corroborated by an informant</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Objective memory impairment (for age and education)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preserved general cognitive function</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intact general functioning</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Not meeting criteria for dementia</p><p></p><p>Memory impairments that qualify for MCI are generally represented by defects that are 1.5 standard deviations (SD) or more below age- and education-corrected norms. This is not an absolute threshold, however, since individuals can experience a significant loss of memory without satisfying that criterion. Different tests of memory likely have different sensitivity and specificity, and norms are not available for all populations; this further justifies the necessity for clinical judgment [<a href="#rid4">4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple domains</strong> – Many individuals with aMCI complain only of memory loss; however, they may have additional impairments in other cognitive domains that are revealed with careful neuropsychological testing [<a href="#rid7">7,16-18</a>]. Such persons may also manifest subtle problems with functioning, but do not meet criteria for a formal diagnosis of dementia [<a href="#rid5">5</a>]. The multiple domains are, by definition, only slightly impaired (ie, less than 1 SD below age- and education-matched normal subjects).</p><p></p><p class="bulletIndent1">These individuals often progress over several years to meet criteria for AD dementia. The prognostic utility of the multiple-domain form of aMCI remains unclear, as some studies have identified this as the highest risk category for conversion to dementia, while others have exposed instability, with some individuals returning to baseline level of function over time [<a href="#rid7">7,19,20</a>]. Much of this variability derives from different sources of subjects (eg, specialty clinics versus population cohorts).</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Nonamnestic MCI</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single domain </strong>– The concept of single-domain naMCI is similar to aMCI, except that this form of MCI is characterized by a relatively isolated impairment in a single nonmemory domain, such as executive functioning, language, or visual spatial skills [<a href="#rid5">5</a>]. Depending upon the domain, individuals with this subtype of MCI may progress to other syndromes, such as vascular cognitive impairment, frontotemporal dementia (FTD), primary progressive aphasia, dementia with Lewy bodies (DLB), progressive supranuclear palsy, or corticobasal degeneration. Individuals within this group appear to be at less of a risk of conversion to dementia, although supporting evidence is limited [<a href="#rid9">9,21-23</a>].</p><p></p><p class="bulletIndent1">In certain disorders such as behavioral variant FTD, cognitive complaints are often preceded by significant alterations in behavior and comportment. Thus, some have proposed the concept of mild behavioral impairment as a similar paradigm to recognize an additional group with increased risk of dementia [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple domains </strong>– Patients who meet these criteria are affected in multiple domains, with a relative sparing of memory problems. The substrate of multidomain naMCI is felt to be that of degenerative disorders associated with tau, TAR DNA binding protein (TDP-43), and alpha-synuclein such as FTD and DLB [<a href="#rid25">25,26</a>]. </p><p></p><p class="bulletIndent1">Other studies have linked MCI in multiple domains to other types of dementia [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/5085.html" rel="external">"Etiology, clinical manifestations, and diagnosis of vascular dementia", section on 'Vascular cognitive impairment'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Related terminology</span><span class="headingEndMark"> — </span>There are many loosely related terms that have been used to describe constructs that are similar to or perhaps even the same as MCI (eg, incipient dementia, isolated memory impairment, dementia prodrome, minimal AD, predementia AD, prodromal AD, and early AD) [<a href="#rid1">1,2,5,6,28,29</a>]. Most of these definitions do not overlap fully with the definition of MCI [<a href="#rid30">30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The concept of MCI perhaps reflects most closely the idea of "<strong>cognitive impairment, no dementia</strong>" (CIND) [<a href="#rid31">31</a>]. However, in contrast to the definition for the amnestic form of MCI, CIND does not require the presence of prominent memory deficits and includes in its definition the presence of a functional disability. In addition, CIND does not necessarily require a change in cognition, such that individuals with longstanding low levels of cognition could qualify. It is a more inclusive definition than MCI, as is reflected by its higher prevalence. (See <a class="local">'Epidemiology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The construct of "<strong>mild neurocognitive disorder</strong>" was introduced in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [<a href="#rid32">32</a>]. Mild neurocognitive disorder is similar to MCI as defined here, and for the clinician, the two entities are equivalent. Mild neurocognitive disorder refers to a condition involving cognitive impairment in one or more domains, often memory, with relative preservation of functioning and the absence of dementia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"<strong>Age-associated memory impairment</strong>" and "<strong>age-associated cognitive decline</strong>" (AACD) are also widely used and fairly well-known terms. However, these terms differ from MCI in that they were originally devised to define normal age-associated memory and cognitive changes in older adults as referenced to young normal adult individuals [<a href="#rid1">1,33,34</a>]. AACD was developed as a way of better defining the cognitive changes in older adult patients compared with age-adjusted norms. AACD has more recently been recognized as identifying a state of impairment similar to MCI [<a href="#rid35">35</a>]. By contrast, MCI refers to an abnormal change in cognitive function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies of "<strong>preclinical AD</strong>" should be distinguished from studies of MCI [<a href="#rid36">36</a>]. In MCI studies, patients meet cognitive criteria for diagnosis, and are then followed prospectively to assess for conversion to dementia. By contrast, preclinical AD refers to individuals with normal cognition who possess positive biomarkers for AD, such as a positive amyloid positron emission tomography (PET) scan or evidence of AD biomarkers in the cerebrospinal fluid (CSF) [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Preclinical Alzheimer disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"<strong>Suspected non-AD pathology (SNAP) MCI</strong>" is a term that is increasingly used in research studies to denote individuals who meet clinical criteria for MCI, show no evidence of amyloid pathology based on CSF biomarker and/or amyloid PET imaging, but have evidence of neuronal injury as measured by either medial temporal lobe atrophy or hypometabolism on 18-F fluorodeoxyglucose PET (FDG-PET) [<a href="#rid38">38,39</a>]. The SNAP designation may be relevant prognostically as well [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'MRI'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>MCI is common in older adult populations, although individual study estimates vary significantly due to differing diagnostic criteria, measuring instruments, and sample populations studied. Based on a meta-analysis of 34 studies conducted by the American Academy of Neurology, the estimated prevalences by age are [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age 60 to 64 years: 6.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Age 65 to 69 years: 8.4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Age 70 to 74 years: 10.1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Age 75 to 79 years: 14.8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Age 80 to 84 years: 25.2 percent</p><p></p><p>Estimates of incidence rates for MCI vary as well; a variety of population-based cohort studies have reported incidence rates in their older adult populations (&gt;65 to 75 years) of between 14 and 111 per 1000 patient-years [<a href="#rid41">41-48</a>]. Amnestic MCI (aMCI) appears to occur more commonly than other subtypes [<a href="#rid46">46</a>]. In the Mayo Clinic Study of Aging, the population-based incidence of MCI in individuals over age 70 years was estimated at 5 to 6 percent per year [<a href="#rid46">46</a>].</p><p>Aside from advancing age, factors most consistently associated with an increased prevalence of MCI include [<a href="#rid4">4,10,40,46,48-62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower educational level</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular risk factors, including hypertension, midlife diabetes, obesity</p><p class="bulletIndent1"><span class="glyph">●</span>History of stroke or heart disease</p><p class="bulletIndent1"><span class="glyph">●</span>Apolipoprotein E (<em>APOE</em>) epsilon 4 genotype</p><p class="bulletIndent1"><span class="glyph">●</span>Neuropsychiatric symptoms (agitation, apathy, depression, anxiety)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Neuropathologic studies suggest that MCI represents an early clinical expression of neurodegenerative disease. Several autopsy studies have found that individuals with MCI (particularly amnestic MCI [aMCI]), as a group, have Alzheimer disease (AD) pathology that is intermediate in severity between normal controls and persons with more advanced AD [<a href="#rid14">14,63-69</a>]. A predominant feature of these studies is the presence of tau deposition in the medial temporal lobes [<a href="#rid64">64</a>].</p><p>Some, but not all, studies find that pathologies consistent with other dementing processes (eg, Lewy body disease and cerebrovascular disease) are also over-represented in the MCI population compared with normal controls, although AD pathology usually predominates [<a href="#rid13">13,63,70-72</a>]. Cerebrovascular and mixed pathologies are especially common among individuals who carry a diagnosis of MCI for a longer interval or die without having progressed to dementia [<a href="#rid73">73</a>]. </p><p>Studies of cholinergic markers in patients with MCI and early to late stages of AD are helping to elucidate the pathogenesis of AD and have challenged the hypothesis that cholinergic dysfunction is responsible for early cognitive dysfunction in this disorder [<a href="#rid66">66,67</a>].</p><p class="headingAnchor" id="H12"><span class="h1">SYMPTOMS</span></p><p class="headingAnchor" id="H13"><span class="h2">Cognitive complaints</span><span class="headingEndMark"> — </span>Patients with MCI, particularly the amnestic subtype, complain primarily of impaired memory. It is important to ascertain that this represents a change from baseline. Subjective memory complaints have been demonstrated to predict cognitive decline, even when patients appear unimpaired on objective testing [<a href="#rid74">74-78</a>]. It is important to note, however, that difficulties with certain aspects of memory, such as recalling names, are frequently reported by normal older adult patients. Subjective reports of memory complaints can often reflect mood or affective state, as well as poor sleep and pain [<a href="#rid74">74,79</a>]. Subjective cognitive complaints may be an insensitive clinical criterion as well as a nonspecific one; some individuals who meet neuropsychological test criteria for MCI deny having significant memory problems [<a href="#rid12">12</a>].</p><p>In contrast to the impaired awareness of deficits commonly present in patients with Alzheimer disease (AD), patients with MCI may be particularly troubled by their symptoms [<a href="#rid76">76,80,81</a>]. However, over time, patients with MCI who convert to AD shift to a relatively greater preponderance of informant-reported symptoms over self-reported symptoms [<a href="#rid82">82</a>]. This phenomenon may be helpful in following an individual patient's progression to dementia.</p><p class="headingAnchor" id="H14"><span class="h2">Neuropsychiatric symptoms</span><span class="headingEndMark"> — </span>As with dementia, mood and behavioral symptoms are more common in patients with MCI than in cognitively unimpaired, age-matched controls [<a href="#rid83">83-88</a>]. The prevalence of depression ranges from 25 to 40 percent [<a href="#rid89">89</a>]; other common symptoms include irritability, anxiety, aggression, and apathy [<a href="#rid85">85</a>]. Patients with behavioral symptoms may be more impaired on cognitive measures than those without behavioral symptoms [<a href="#rid85">85</a>]. Population-based studies comparing MCI and AD patients find a similar range of neuropsychiatric symptoms, with AD patients having them in somewhat higher frequency and severity [<a href="#rid86">86,90,91</a>]. (See  <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p>The relationship between depression and cognitive impairment is complicated. Cognitive impairment may be a presenting symptom of depression, so-called pseudodementia or dementia syndrome of depression. Depression may also be an early manifestation of cognitive impairment. (See  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.)</p><p>A number of population-based studies have found an association between various measures of depression and either the presence or incidence of MCI [<a href="#rid83">83,92-98</a>]. However, follow-up data have yielded somewhat mixed results. In the aggregate, these results appear to suggest that depression may be an early manifestation of cognitive decline and possibly an independent risk factor for MCI or progression to dementia. At the least, these studies highlight the importance of recognizing the symptoms of mood and behavioral changes in patients reporting memory problems, as they may represent a group at increased risk of developing dementia, and warrant closer follow-up.</p><p class="headingAnchor" id="H16"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2220626635"><span class="h2">Goals of the evaluation</span><span class="headingEndMark"> — </span>The evaluation of patients who present with cognitive complaints is focused on establishing the severity of the impairments and providing a baseline for follow-up. Individuals with MCI are at increased risk of progressing to dementia, and clinicians should not assume that concerns about impaired cognition are related to normal aging without proper evaluation. Accurate diagnosis of MCI is important in order to [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Assess for reversible causes of cognitive impairment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Help patients and families understand the cause of their cognitive concerns</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discuss prognostic significance of a diagnosis of MCI and help patients and families plan for the future</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Office evaluation</span><span class="headingEndMark"> — </span>The cornerstone of any evaluation of someone with memory loss is the clinical interview. Ideally, an informant will be available, and if not, attempts should be made to contact one. The goals are to assess the severity of memory loss and the degree, if any, of functional impairment that limits independence in daily activities [<a href="#rid40">40</a>]. Although the boundary is not always clear, functional impairment is a key indicator that distinguishes dementia from MCI.</p><p>By discussing current events involving a variety of topics, it is often possible to develop a sense of the degree of amnestic problems. Discussing premorbid and current financial competence with patients and family members can be another useful measure of cognitive status that may be particularly sensitive to early decline [<a href="#rid99">99</a>]. Clear functional decline such as difficulties with activities of daily living may be a later, but more specific, finding for early dementia [<a href="#rid100">100</a>].</p><p>A brief, comprehensive evaluation of the patient's cognitive profile should also be performed. Clinicians should not rely on historical report of subjective memory concerns alone. Examples of brief, validated cognitive assessments include the Folstein Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) [<a href="#rid101">101-104</a>]. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Cognitive testing'</a>.)</p><p>Other essential aspects of the office evaluation include:</p><p class="bulletIndent1"><span class="glyph">●</span>A comprehensive medical and neurologic examination must be performed to identify sources of nondegenerative causes of cognitive change. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A medication list should be reviewed to identify those medications associated with adverse cognitive effects. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A sleep history should be obtained to identify potential dementia-related sleep disturbances as well as sleep disorders that might be contributing to cognitive impairment. (See  <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia", section on 'Sleep disturbances'</a> and  <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia", section on 'Obstructive sleep apnea'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying psychiatric conditions should also be probed. (See  <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">"Screening for depression in adults"</a>.) </p><p></p><p class="headingAnchor" id="H18"><span class="h2">Neuropsychological testing</span><span class="headingEndMark"> — </span>Patients who screen positive for MCI by history and brief cognitive assessment should have more in-depth cognitive testing, such as neuropsychological testing with interpretation based on appropriate normative data [<a href="#rid40">40</a>].</p><p>Neuropsychological testing includes an objective measure of memory impairment [<a href="#rid5">5</a>]. It may also have additional value in the detection of contributing or causative depression.</p><p>Neuropsychological testing should not be used in isolation; clinical judgment is critical to diagnosing both dementia and MCI [<a href="#rid10">10,80</a>]. There are no uniformly accepted criteria for the diagnosis of MCI using neuropsychological testing. Some suggest a 1.5 standard deviation (SD) threshold value for tests of memory impairment; others have used 1 SD [<a href="#rid1">1,4,33,105</a>]. These appear to be the appropriate ranges for most individuals diagnosed with MCI, but these data must be used in the context of the history of the individual. In amnestic MCI (aMCI), other cognitive domains may be impaired, but test abnormalities are generally milder and are usually within 0.5 SD of appropriate comparison groups. In multiple-domain MCI, several cognitive domains may be impaired in the 0.5 to 1.0 SD range. These ranges are not used as cutoff scores, but they provide a sense of the impairments seen in MCI.</p><p>Some rating scales are useful for characterizing the stage of impairment but are not substitutes for the clinical diagnosis of MCI. The Clinical Dementia Rating (CDR) scale and the Global Deterioration Scale (GDS) are useful adjuncts for the clinician in characterizing the degree of impairment. For example, a CDR of 0.5 commonly refers to the degree of impairment between normal aging and mild dementia. However, patients with MCI can have a CDR rating of 0 or 0.5 due to the subtle degrees of impairment without a functional decline. Since the CDR largely involves the subjective perceptions of the patient and an informant, judgments may vary from the clinician's impression of the degree of impairment. Similarly, with the GDS, Stages 2 and 3 can be conflated due to the patient's and informant's perception. Thus, while the scales are useful for estimating impairment, they are not adequate for the diagnosis of MCI [<a href="#rid106">106</a>].</p><p>For patients who meet criteria for MCI or have persistent cognitive complaints, neuropsychological reassessment in approximately one year is recommended to monitor cognitive and functional decline [<a href="#rid6">6</a>]. Improved performance on the examination argues against neurodegenerative disease, while declining performance supports that diagnosis, even before a threshold level for dementia has been reached [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Progression to dementia'</a> and  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Neuropsychological testing'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>The role of neuroimaging, brain computed tomography (CT) or magnetic resonance imaging (MRI), in the evaluation of MCI is evolving. </p><p>We order noncontrast brain MRI with coronal slices to image the hippocampus in patients with MCI. Others may take the view that CT scan can adequately evaluate for cerebrovascular disease, subdural hematoma, normal pressure hydrocephalus, or mass lesion that might cause clinically significant cognitive deficits. However, MRI is more sensitive than CT in assessing focal patterns of atrophy, such as temporal lobe volume loss; this last finding may indicate an individual at particularly high risk of converting from MCI to dementia. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'MRI'</a>.)</p><p>In addition, MRI may be more sensitive than CT in identifying cerebrovascular disease, another finding that may identify patients at higher risk of progressing to dementia and who might additionally benefit from more aggressive treatment of vascular comorbidities. (See  <a class="medical medical_review" href="/z/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia", section on 'Vascular risk modification'</a> and  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Cerebrovascular risk factors'</a>.)</p><p>The role of other neuroimaging tests, including positron emission tomography (PET), functional MRI, PET amyloid imaging, and single-photon emission CT (SPECT), in assessing the risk for and type of neurodegenerative dementia is evolving. (See  <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Neuroimaging'</a>.)</p><p>Data from the Alzheimer Disease Neuroimaging Initiative document the utility of imaging biomarkers such as amyloid PET in predicting progression [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Amyloid PET'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Other testing</span><span class="headingEndMark"> — </span>Treatable conditions should also be ruled out. In general, the evaluation of patients with MCI should be similar to that performed in patients presenting with dementia and include a neuroimaging study (brain CT or MRI) and screening for B12 deficiency, hypothyroidism, and evaluation for depression. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia"</a>.)</p><p>Ongoing investigations are examining the relationship between apolipoprotein E (<em>APOE</em>) genotype and/or the levels of certain biomarkers within the cerebrospinal fluid (CSF) and the risk of converting from MCI to dementia. At the present time, there is no clinical imperative for these tests. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Predictors'</a>.)</p><p class="headingAnchor" id="H57535961"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Clinical judgment is critical to diagnosing MCI [<a href="#rid10">10,80</a>]. There are no uniformly accepted criteria for the diagnosis of MCI using neuropsychological testing or other cognitive assessments. MCI is ultimately a clinical diagnosis that considers the individual's expected level of cognitive function. In the absence of clear evidence that an individual's performance on cognitive testing represents a clear decline, a diagnosis of MCI should be withheld, even if scores meet criteria for MCI.</p><p>A workgroup on diagnostic guidelines from the National Institute on Aging and the Alzheimer's Association identified the following core clinical features that indicate MCI due to Alzheimer disease (AD) [<a href="#rid108">108</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive concern reflecting a change in cognition reported by patient or informant or observed by clinician</p><p class="bulletIndent1"><span class="glyph">●</span>Objective evidence of impairment in one or more cognitive domains, typically including memory</p><p class="bulletIndent1"><span class="glyph">●</span>Preservation of independence in functional abilities</p><p class="bulletIndent1"><span class="glyph">●</span>Not demented</p><p></p><p>These criteria only refer to the subset of all MCI that is thought be due to AD, and not to MCI due to other etiologies, eg, vascular disease, other neurodegenerative conditions, or psychiatric conditions [<a href="#rid8">8</a>].</p><p>In addition, the etiology of MCI should be evaluated to identify a cause other than AD (see <a class="local">'Evaluation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Identify or rule out vascular, traumatic, medical causes of cognitive decline, where possible</p><p class="bulletIndent1"><span class="glyph">●</span>Provide evidence of longitudinal decline in cognition, when feasible</p><p class="bulletIndent1"><span class="glyph">●</span>Identify other clinical features that may suggest a specific neurodegenerative syndrome (eg, parkinsonism)</p><p class="bulletIndent1"><span class="glyph">●</span>Report history consistent with AD genetic factors, where relevant</p><p></p><p class="headingAnchor" id="H57535968"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>While MCI is associated with the risk of Alzheimer disease (AD), other neurodegenerative dementias, and vascular dementia, other conditions can also present with MCI.</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric disease, particularly depression, may present with cognitive rather than mood complaints.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects of medications (eg, anticholinergic, antihistamine use) and sleep disturbances are also common causes of cognitive complaints, particularly in older adult populations [<a href="#rid109">109,110</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic disturbances, particularly vitamin B12 deficiency and hypothyroidism, should be considered in the differential diagnosis of MCI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal aging can be associated with both subjective and objective cognitive changes. In general, these are not sufficiently severe to be of concern and are not accompanied by loss of functional abilities in daily life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Structural brain disease is an uncommon cause of MCI in the absence of focal neurologic findings.</p><p></p><p>In one community sample, patients with "cognitive impairment, no dementia" (CIND) were diagnosed with depression and other psychiatric disease (10.2 percent), alcohol- and drug-related causes (6.9 percent), and delirium (1 percent) [<a href="#rid31">31</a>]. Approximately one-quarter of cases had neurologic disease (brain tumor, Parkinson disease, multiple sclerosis, cerebrovascular disease, and epilepsy). Among the remaining 57.5 percent, most (31.7 percent) had circumscribed memory impairment.</p><p class="headingAnchor" id="H2226096382"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H3544469"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16836.html" rel="external">"Patient education: Evaluating memory and thinking problems (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16423.html" rel="external">"Patient education: Mild cognitive impairment (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Mild cognitive impairment (MCI) represents a state between normal aging and dementia.</p><p class="bulletIndent1"><span class="glyph">●</span>MCI includes patients with cognitive deficits that are insufficiently severe to meet criteria for dementia but are more severe than those associated with normal aging. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Types of MCI based on the affected cognitive domains (amnestic MCI [aMCI], nonamnestic MCI [naMCI]) are individually recognized with subtypes of single- and multiple-domain classifications. These clinical subtypes are believed to have value in predicting conversion to a specific type of dementia. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic studies of individuals with MCI generally reveal pathology of neurodegenerative or cerebrovascular disease that is intermediate between cognitively normal and demented adults. Alzheimer-type pathology typically predominates, particularly among those with aMCI. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians should consider potentially treatable causes of cognitive impairment, such as psychiatric disease, the effects of medications, and underlying medical conditions. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Office evaluation'</a> above and <a class="local">'Other testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend neuropsychological testing in individuals suspected of having MCI. Those meeting criteria for MCI and those with prominent subjective complaints should have follow-up testing to evaluate for progression between one and two years after the initial assessment. (See <a class="local">'Neuropsychological testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, a number of screening mental status scales can be performed during office examinations for evidence of cognitive decline. (See <a class="local">'Office evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend a brain magnetic resonance imaging (MRI) study be performed in individuals with MCI to exclude structural disease and assess the extent of cerebrovascular disease and regional atrophy. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="headingAnchor" id="H159579291"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Eric M McDade, DO, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56:303.</a></li><li><a class="nounderline abstract_t">Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment--A review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand 2002; 106:403.</a></li><li><a class="nounderline abstract_t">Voisin T, Touchon J, Vellas B. Mild cognitive impairment: A nosological entity? Curr Opin Neurol 2003; 16 Suppl 2:S43.</a></li><li><a class="nounderline abstract_t">Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: An epidemiologic study. Neurology 2004; 63:115.</a></li><li class="breakAll">Petersen RC. Conceptual overview. In: Mild Cognitive Impairment: Aging to Alzheimer's Disease, Petersen RC (Ed), Oxford University Press, New York 2003. p.1.</li><li><a class="nounderline abstract_t">Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1133.</a></li><li><a class="nounderline abstract_t">Salmon D, Hodges JR. Introduction: Mild cognitive impairment--cognitive, behavioral, and biological factors. Neurocase 2005; 11:1.</a></li><li><a class="nounderline abstract_t">Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183.</a></li><li><a class="nounderline abstract_t">Busse A, Hensel A, Gühne U, et al. Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology 2006; 67:2176.</a></li><li><a class="nounderline abstract_t">Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: A population-based validation study. Neurology 2001; 56:37.</a></li><li><a class="nounderline abstract_t">Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology 2003; 61:1179.</a></li><li><a class="nounderline abstract_t">Mitchell AJ. Is it time to separate subjective cognitive complaints from the diagnosis of mild cognitive impairment? Age Ageing 2008; 37:497.</a></li><li><a class="nounderline abstract_t">Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58:397.</a></li><li><a class="nounderline abstract_t">Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: Ten years later. Arch Neurol 2009; 66:1447.</a></li><li><a class="nounderline abstract_t">Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008; 30:58.</a></li><li><a class="nounderline abstract_t">Bozoki A, Giordani B, Heidebrink JL, et al. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001; 58:411.</a></li><li><a class="nounderline abstract_t">DeCarli C. Mild cognitive impairment: Prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2:15.</a></li><li><a class="nounderline abstract_t">Nordlund A, Rolstad S, Hellström P, et al. The Goteborg MCI study: Mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005; 76:1485.</a></li><li><a class="nounderline abstract_t">Rasquin SM, Lodder J, Visser PJ, et al. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: A 2-year follow-up study. Dement Geriatr Cogn Disord 2005; 19:113.</a></li><li><a class="nounderline abstract_t">Alexopoulos P, Grimmer T, Perneczky R, et al. Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2006; 22:27.</a></li><li><a class="nounderline abstract_t">Matthews FE, Stephan BC, McKeith IG, et al. Two-year progression from mild cognitive impairment to dementia: To what extent do different definitions agree? J Am Geriatr Soc 2008; 56:1424.</a></li><li><a class="nounderline abstract_t">Ferman TJ, Smith GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 2013; 81:2032.</a></li><li><a class="nounderline abstract_t">Jung Y, Boot BP, Mielke MM, et al. Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample. Alzheimers Dement (Amst) 2017; 8:127.</a></li><li><a class="nounderline abstract_t">Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment and risk of dementia: A prospective cohort study of 358 patients. J Clin Psychiatry 2009; 70:584.</a></li><li><a class="nounderline abstract_t">Kwong LK, Neumann M, Sampathu DM, et al. TDP-43 proteinopathy: The neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol 2007; 114:63.</a></li><li><a class="nounderline abstract_t">Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: A clinicopathological study. Brain 2010; 133:540.</a></li><li><a class="nounderline abstract_t">Zanetti M, Ballabio C, Abbate C, et al. Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: A 3-year follow-up study. J Am Geriatr Soc 2006; 54:580.</a></li><li><a class="nounderline abstract_t">Stokholm J, Jakobsen O, Czarna JM, et al. Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease. Neurocase 2005; 11:48.</a></li><li><a class="nounderline abstract_t">Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004; 10 Suppl:S34.</a></li><li><a class="nounderline abstract_t">Ritchie K, Touchon J. Mild cognitive impairment: Conceptual basis and current nosological status. Lancet 2000; 355:225.</a></li><li><a class="nounderline abstract_t">Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349:1793.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Crook TH, Bartus RT, Ferris SH, et al. Age-associated memory impairment: Proposed diagnostic criteria measures clinical change - Report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986; 2:261.</a></li><li><a class="nounderline abstract_t">Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994; 6:63.</a></li><li><a class="nounderline abstract_t">Richards M, Touchon J, Ledesert B, Richie K. Cognitive decline in ageing: Are AAMI and AACD distinct entities? Int J Geriatr Psychiatry 1999; 14:534.</a></li><li><a class="nounderline abstract_t">Small BJ, Mobly JL, Laukka EJ, et al. Cognitive deficits in preclinical Alzheimer's disease. Acta Neurol Scand Suppl 2003; 179:29.</a></li><li><a class="nounderline abstract_t">Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280.</a></li><li><a class="nounderline abstract_t">Caroli A, Prestia A, Galluzzi S, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology 2015; 84:508.</a></li><li><a class="nounderline abstract_t">Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013; 74:199.</a></li><li><a class="nounderline abstract_t">Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:126.</a></li><li><a class="nounderline abstract_t">Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63:494.</a></li><li><a class="nounderline abstract_t">Caracciolo B, Palmer K, Monastero R, et al. Occurrence of cognitive impairment and dementia in the community: A 9-year-long prospective study. Neurology 2008; 70:1778.</a></li><li><a class="nounderline abstract_t">Luck T, Luppa M, Briel S, et al. Mild cognitive impairment: Incidence and risk factors: Results of the leipzig longitudinal study of the aged. J Am Geriatr Soc 2010; 58:1903.</a></li><li><a class="nounderline abstract_t">Luck T, Luppa M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: A systematic review. Dement Geriatr Cogn Disord 2010; 29:164.</a></li><li><a class="nounderline abstract_t">Plassman BL, Langa KM, McCammon RJ, et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol 2011; 70:418.</a></li><li><a class="nounderline abstract_t">Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. Neurology 2012; 78:342.</a></li><li><a class="nounderline abstract_t">Lopez OL, Becker JT, Chang YF, et al. Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 2012; 79:1599.</a></li><li><a class="nounderline abstract_t">Ganguli M, Fu B, Snitz BE, et al. Mild cognitive impairment: Incidence and vascular risk factors in a population-based cohort. Neurology 2013; 80:2112.</a></li><li><a class="nounderline abstract_t">Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: The Cache County Study. Neurology 2006; 67:229.</a></li><li><a class="nounderline abstract_t">Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 2003; 60:1385.</a></li><li><a class="nounderline abstract_t">Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 2010; 75:889.</a></li><li><a class="nounderline abstract_t">Manly JJ, Bell-McGinty S, Tang MX, et al. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 2005; 62:1739.</a></li><li><a class="nounderline abstract_t">Kryscio RJ, Schmitt FA, Salazar JC, et al. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006; 66:828.</a></li><li><a class="nounderline abstract_t">Das SK, Bose P, Biswas A, et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 2007; 68:2019.</a></li><li><a class="nounderline abstract_t">Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: Findings from the Nun Study. Am J Epidemiol 2007; 165:1231.</a></li><li><a class="nounderline abstract_t">DeCarli C, Miller BL, Swan GE, et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001; 58:643.</a></li><li><a class="nounderline abstract_t">Reitz C, Tang MX, Manly J, et al. Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007; 64:1734.</a></li><li><a class="nounderline abstract_t">Roberts RO, Geda YE, Knopman DS, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008; 65:1066.</a></li><li><a class="nounderline abstract_t">Schultz MR, Lyons MJ, Franz CE, et al. Apolipoprotein E genotype and memory in the sixth decade of life. Neurology 2008; 70:1771.</a></li><li><a class="nounderline abstract_t">Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology 2004; 63:1898.</a></li><li><a class="nounderline abstract_t">Boyle PA, Buchman AS, Wilson RS, et al. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010; 34:43.</a></li><li><a class="nounderline abstract_t">Geda YE, Roberts RO, Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study. Am J Psychiatry 2014; 171:572.</a></li><li><a class="nounderline abstract_t">Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64:834.</a></li><li><a class="nounderline abstract_t">Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63:665.</a></li><li><a class="nounderline abstract_t">Sabbagh MN, Shah F, Reid RT, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 2006; 63:1771.</a></li><li><a class="nounderline abstract_t">Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281:1401.</a></li><li><a class="nounderline abstract_t">DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51:145.</a></li><li><a class="nounderline abstract_t">Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006; 63:38.</a></li><li><a class="nounderline abstract_t">Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003; 60:729.</a></li><li><a class="nounderline abstract_t">Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63:674.</a></li><li><a class="nounderline abstract_t">Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66:200.</a></li><li><a class="nounderline abstract_t">Wilson RS, Leurgans SE, Boyle PA, et al. Neurodegenerative basis of age-related cognitive decline. Neurology 2010; 75:1070.</a></li><li><a class="nounderline abstract_t">Abner EL, Kryscio RJ, Schmitt FA, et al. Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol 2017; 81:549.</a></li><li><a class="nounderline abstract_t">Tobiansky R, Blizard R, Livingston G, Mann A. The Gospel Oak Study stage IV: The clinical relevance of subjective memory impairment in older people. Psychol Med 1995; 25:779.</a></li><li><a class="nounderline abstract_t">Geerlings MI, Jonker C, Bouter LM, et al. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999; 156:531.</a></li><li><a class="nounderline abstract_t">van Norden AG, Fick WF, de Laat KF, et al. Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology 2008; 71:1152.</a></li><li><a class="nounderline abstract_t">Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012; 79:1332.</a></li><li><a class="nounderline abstract_t">Mitchell AJ, Beaumont H, Ferguson D, et al. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr Scand 2014; 130:439.</a></li><li><a class="nounderline abstract_t">Riedel-Heller SG, Matschinger H, Schork A, Angermeyer MC. Do memory complaints indicate the presence of cognitive impairment? Results of a field study. Eur Arch Psychiatry Clin Neurosci 1999; 249:197.</a></li><li><a class="nounderline abstract_t">Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58:1985.</a></li><li><a class="nounderline abstract_t">Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70:1601.</a></li><li><a class="nounderline abstract_t">Tabert MH, Albert SM, Borukhova-Milov L, et al. Functional deficits in patients with mild cognitive impairment: Prediction of AD. Neurology 2002; 58:758.</a></li><li><a class="nounderline abstract_t">Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007; 68:1596.</a></li><li><a class="nounderline abstract_t">Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology 2004; 62:1199.</a></li><li><a class="nounderline abstract_t">Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: Population-based study. Arch Gen Psychiatry 2008; 65:1193.</a></li><li><a class="nounderline abstract_t">Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: The aging, demographics, and memory study. J Am Geriatr Soc 2010; 58:330.</a></li><li><a class="nounderline abstract_t">Gabryelewicz T, Styczynska M, Pfeffer A, et al. Prevalence of major and minor depression in elderly persons with mild cognitive impairment--MADRS factor analysis. Int J Geriatr Psychiatry 2004; 19:1168.</a></li><li><a class="nounderline abstract_t">Kumar R, Jorm AF, Parslow RA, Sachdev PS. Depression in mild cognitive impairment in a community sample of individuals 60-64 years old. Int Psychogeriatr 2006; 18:471.</a></li><li><a class="nounderline abstract_t">Ismail Z, Elbayoumi H, Fischer CE, et al. Prevalence of depression in patients with mild cognitive impairment: A systematic review and meta-analysis. JAMA Psychiatry 2017; 74:58.</a></li><li><a class="nounderline abstract_t">Lopez OL, Becker JT, Sweet RA. Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase 2005; 11:65.</a></li><li><a class="nounderline abstract_t">Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002; 288:1475.</a></li><li><a class="nounderline abstract_t">Vinkers DJ, Gussekloo J, Stek ML, et al. Temporal relation between depression and cognitive impairment in old age: Prospective population based study. BMJ 2004; 329:881.</a></li><li><a class="nounderline abstract_t">Wilson RS, Schneider JA, Boyle PA, et al. Chronic distress and incidence of mild cognitive impairment. Neurology 2007; 68:2085.</a></li><li><a class="nounderline abstract_t">Geda YE, Knopman DS, Mrazek DA, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: A prospective cohort study. Arch Neurol 2006; 63:435.</a></li><li><a class="nounderline abstract_t">Goveas JS, Espeland MA, Woods NF, et al. Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: The Women's Health Initiative Memory Study. J Am Geriatr Soc 2011; 59:57.</a></li><li><a class="nounderline abstract_t">Caracciolo B, Bäckman L, Monastero R, et al. The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: A cohort study of a community dwelling elderly population. J Neurol Neurosurg Psychiatry 2011; 82:788.</a></li><li><a class="nounderline abstract_t">Wilson RS, Arnold SE, Beck TL, et al. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry 2008; 65:439.</a></li><li><a class="nounderline abstract_t">Wilson RS, Hoganson GM, Rajan KB, et al. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 2010; 75:21.</a></li><li><a class="nounderline abstract_t">Triebel KL, Martin R, Griffith HR, et al. Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study. Neurology 2009; 73:928.</a></li><li><a class="nounderline abstract_t">Chang YL, Bondi MW, McEvoy LK, et al. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology 2011; 76:652.</a></li><li><a class="nounderline abstract_t">Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.</a></li><li><a class="nounderline abstract_t">Kokmen E, Smith GE, Petersen RC, et al. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991; 48:725.</a></li><li><a class="nounderline abstract_t">Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695.</a></li><li><a class="nounderline abstract_t">Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol 2003; 60:1777.</a></li><li><a class="nounderline abstract_t">Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379.</a></li><li><a class="nounderline abstract_t">Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008; 148:427.</a></li><li><a class="nounderline abstract_t">Petersen RC, Caracciolo B, Brayne C, et al. Mild cognitive impairment: A concept in evolution. J Intern Med 2014; 275:214.</a></li><li><a class="nounderline abstract_t">Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270.</a></li><li><a class="nounderline abstract_t">Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc 2007; 55:1248.</a></li><li><a class="nounderline abstract_t">Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch Intern Med 2009; 169:1317.</a></li></ol></div><div id="topicVersionRevision">Topic 5081 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190820" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mild cognitive impairment: clinical characterization and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392483" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mild cognitive impairment--a review of prevalence, incidence and outcome according to current approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15129850" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mild cognitive impairment: a nosological entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249620" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mild cognitive impairment, amnestic type: an epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249620" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mild cognitive impairment, amnestic type: an epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342677" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804917" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Introduction: mild cognitive impairment--cognitive, behavioral, and biological factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15324362" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mild cognitive impairment as a diagnostic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190940" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mild cognitive impairment: long-term course of four clinical subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148233" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Classification criteria for mild cognitive impairment: a population-based validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14610117" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Variations in case definition affect prevalence but not outcomes of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682432" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Is it time to separate subjective cognitive complaints from the diagnosis of mild cognitive impairment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255443" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mild cognitive impairment represents early-stage Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008648" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mild cognitive impairment: ten years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18259084" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255444" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849297" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227535" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591801" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679762" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Progression to dementia in clinical subtypes of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18662209" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24212390" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28649596" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323967" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17492294" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889717" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686866" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: a 3-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804924" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15298007" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Advances in the early detection of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675135" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mild cognitive impairment: conceptual basis and current nosological status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269213" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence and severity of cognitive impairment with and without dementia in an elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269213" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence and severity of cognitive impairment with and without dementia in an elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Age-associated memory impairment: proposed diagnostic criteria measures clinical change - report of a National Institute of Mental Health Work Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8054494" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440973" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cognitive decline in ageing: are AAMI and AACD distinct entities?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12603248" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cognitive deficits in preclinical Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514248" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568301" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686697" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mild cognitive impairment due to Alzheimer disease in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282327" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300306" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Frequency and course of mild cognitive impairment in a multiethnic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184916" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Occurrence of cognitive impairment and dementia in the community: a 9-year-long prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20840461" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mild cognitive impairment: incidence and risk factors: results of the leipzig longitudinal study of the aged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150735" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence of mild cognitive impairment: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21425187" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Incidence of dementia and cognitive impairment, not dementia in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282647" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019262" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23658380" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864813" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Conversion to dementia from mild cognitive disorder: the Cache County Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568808" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20820000" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286549" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567698" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk factors for transitions from normal to mild cognitive impairment and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548552" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : An epidemiologic study of mild cognitive impairment in Kolkata, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431012" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11295996" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071036" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hypertension and the risk of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18695056" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association of duration and severity of diabetes mellitus with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18235080" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Apolipoprotein E genotype and memory in the sixth decade of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557508" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of APOE in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907191" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700290" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753419" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682536" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Neuropathologic features of amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17172618" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10217056" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cholinergic markers in elderly patients with early signs of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11835370" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401735" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Neuropathologic substrate of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12756137" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682537" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19743450" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The neuropathology of probable Alzheimer disease and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844243" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Neurodegenerative basis of age-related cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28224671" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Outcomes after diagnosis of mild cognitive impairment in a large autopsy series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7480455" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The Gospel Oak Study stage IV: the clinical relevance of subjective memory impairment in older people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200730" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838662" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Subjective cognitive failures and hippocampal volume in elderly with white matter lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914828" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25219393" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449595" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Do memory complaints indicate the presence of cognitive impairment? Results of a field study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11735772" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Current concepts in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443310" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Neuroimaging correlates of subjective memory deficits in a community population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889240" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Functional deficits in patients with mild cognitive impairment: prediction of AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485646" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Predictors of progression from mild cognitive impairment to Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079026" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Behavioral symptoms in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838636" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20374406" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15526303" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevalence of major and minor depression in elderly persons with mild cognitive impairment--MADRS factor analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16466589" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Depression in mild cognitive impairment in a community sample of individuals 60-64 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893026" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prevalence of Depression in Patients With Mild Cognitive Impairment: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804926" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Non-cognitive symptoms in mild cognitive impairment subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243634" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15345599" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Temporal relation between depression and cognitive impairment in old age: prospective population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562829" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Chronic distress and incidence of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16533972" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226676" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21212108" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391132" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Change in depressive symptoms during the prodromal phase of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20603481" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Temporal course of depressive symptoms during the development of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770468" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321338" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Global clinical dementia rating of 0.5 in MCI masks variability related to level of function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1202204" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1859300" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The short test of mental status. Correlations with standardized psychometric testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817019" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14676056" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829527" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Vitamin E and donepezil for the treatment of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347351" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prevalence of cognitive impairment without dementia in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24605806" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Mild cognitive impairment: a concept in evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514249" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17661965" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The association between cognition and histamine-2 receptor antagonists in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636034" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
